Zentalis Pharmaceuticals Llc (ZNTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.94 Million) by net assets ($216.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ZNTL stock market capitalisation for the company's overall valuation and market capitalisation.
Zentalis Pharmaceuticals Llc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zentalis Pharmaceuticals Llc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their cash flow conversion efficiency. Explore earnings quality score of Zentalis Pharmaceuticals Llc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brockhaus Capital Management AG
F:BKHT
|
0.059x |
|
Pioneer Municipal High Income Opportunities Fund Inc
NYSE:MIO
|
-1.549x |
|
Smec Co.Ltd
KQ:099440
|
0.089x |
|
Tornado Global Hydrovacs Ltd
V:TGH
|
0.209x |
|
Hua Na Hydropower JSC
VN:HNA
|
0.038x |
|
Steyr Motors AG
VI:4X0
|
N/A |
|
Hwacom Systems
TWO:6163
|
0.237x |
|
KlaraBo Sverige AB Series B
ST:KLARA-B
|
0.001x |
Annual Cash Flow Conversion Efficiency for Zentalis Pharmaceuticals Llc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Zentalis Pharmaceuticals Llc from 2018 to 2025. View ZNTL live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $216.20 Million | $-125.25 Million | -0.579x | -14.32% |
| 2024-12-31 | $337.19 Million | $-170.86 Million | -0.507x | -6.65% |
| 2023-12-31 | $437.39 Million | $-207.82 Million | -0.475x | -25.94% |
| 2022-12-31 | $434.02 Million | $-163.75 Million | -0.377x | +10.76% |
| 2021-12-31 | $364.48 Million | $-154.09 Million | -0.423x | -62.33% |
| 2020-12-31 | $333.38 Million | $-86.83 Million | -0.260x | +54.48% |
| 2019-12-31 | $68.42 Million | $-39.14 Million | -0.572x | +23.79% |
| 2018-12-31 | $32.31 Million | $-24.25 Million | -0.751x | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more